0000890821 false --12-31 0000890821
2022-05-03 2022-05-03 iso4217:USD xbrli:shares iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
Current
Report
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported):
May 3, 2022
Enveric Biosciences, Inc.
(Exact
name of Registrant as specified in its charter)
Delaware |
|
001-38286 |
|
95-4484725 |
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
No.)
|
|
(IRS
Employer
Identification
No.)
|
Enveric
Biosciences, Inc.
4851 Tamiami Trail N,
Suite 200
Naples,
FL
34103
(Address
of principal executive offices and zip code)
Registrant’s
telephone number, including area code:
(239)
302-1707
N/A
(Former
name or former address, if changed since last
report.)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common stock, par value $0.01 per share |
|
ENVB |
|
The Nasdaq Stock Market |
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
Emerging
growth company
☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item
3.03. Material Modification to Rights of Security
Holders.
The
disclosure set forth in Item 5.03 below is hereby incorporated
herein by reference.
Item
5.03. Amendments to Articles of Incorporation or Bylaws; Change in
Fiscal Year.
Series C Preferred Stock
On
May 3, 2022, the board of directors (the “Board”) of
Enveric Biosciences, Inc. (the “Company”), declared a
dividend of one one-thousandth of a share of Series C Preferred
Stock, par value $0.01 per share (“Series C Preferred
Stock”), for each outstanding share of the Company’s common
stock, par value $0.01 per share (“Common Stock”) to
stockholders of record at 5:00 p.m. Eastern Time on May 13, 2022
(the “Record Date”).
General; Transferability. Shares of Series C Preferred
Stock will be uncertificated and represented in book-entry form. No
shares of Series C Preferred Stock may be transferred by the holder
thereof except in connection with a transfer by such holder of any
shares of Common Stock held by such holder, in which case a number
of one one-thousandths (1/1,000ths) of a share of Series C
Preferred Stock equal to the number of shares of Common Stock to be
transferred by such holder will be automatically transferred to the
transferee of such shares of Common Stock.
Voting Rights. Each share of Series C Preferred
Stock will entitle the holder thereof to 1,000,000 votes per share
(and, for the avoidance of doubt, each fraction of a share of
Series C Preferred Stock will have a ratable number of votes).
Thus, each one-thousandth of a share of Series C Preferred Stock
would entitle the holder thereof to 1,000 votes. The outstanding
shares of Series C Preferred Stock will vote together with the
outstanding shares of Common Stock of the Company as a single class
exclusively with respect to (1) any proposal to adopt an amendment
to the Company’s Amended and Restated Certificate of Incorporation,
as amended (the “Certificate of Incorporation”), to
reclassify the outstanding shares of Common Stock into a smaller
number of shares of Common Stock at a ratio specified in or
determined in accordance with the terms of such amendment (the
“Reverse Stock Split”), (2) any proposal to adopt an
amendment to the Certificate of Incorporation to increase the
number of authorized shares of the Corporation’s Common Stock (the
“Share Increase Proposal”) and (3) any proposal to
adjourn any meeting of stockholders called for the purpose of
voting on Reverse Stock Split or the Share Increase Proposal (the
“Adjournment Proposal”). The Series C Preferred Stock
will not be entitled to vote on any other matter, except to the
extent required under the Delaware General Corporation
Law.
Unless
otherwise provided on any applicable proxy or ballot with respect
to the voting on the Reverse Stock Split, the Share Increase
Proposal or the Adjournment Proposal, the vote of each share of
Series C Preferred Stock (or fraction thereof) entitled to vote on
the Reverse Stock Split, the Share Increase Proposal, the
Adjournment Proposal or any other matter brought before any meeting
of stockholders held to vote on the Reverse Stock Split, the Share
Increase Proposal and the Adjournment Proposal shall be cast in the
same manner as the vote, if any, of the share of Common Stock (or
fraction thereof) in respect of which such share of Series C
Preferred Stock (or fraction thereof) was issued as a dividend is
cast on the Reverse Stock Split, the Share Increase Proposal, the
Adjournment Proposal or such other matter, as applicable, and the
proxy or ballot with respect to shares of Common Stock held by any
holder on whose behalf such proxy or ballot is submitted will be
deemed to include all shares of Series C Preferred Stock (or
fraction thereof) held by such holder. Holders of Series C
Preferred Stock will not receive a separate ballot or proxy to cast
votes with respect to the Series C Preferred Stock on the Reverse
Stock Split, the Share Increase Proposal, the Adjournment Proposal
or any other matter brought before any meeting of stockholders held
to vote on the Reverse Stock Split or the Share Increase
Proposal.
Dividend Rights. The holders of Series C Preferred Stock,
as such, will not be entitled to receive dividends of any
kind.
Liquidation Preference. The Series C Preferred Stock will
rank senior to the Common Stock as to any distribution of assets
upon a liquidation, dissolution or winding up of the Company,
whether voluntarily or involuntarily (a
“Dissolution”). Upon any Dissolution, each holder of
outstanding shares of Series C Preferred Stock will be entitled to
be paid out of the assets of the Company available for distribution
to stockholders, prior and in preference to any distribution to the
holders of Common Stock, an amount in cash equal to $0.01 per
outstanding share of Series C Preferred Stock.
Redemption. All shares of Series C Preferred Stock that are
not present in person or by proxy at any meeting of stockholders
held to vote on the Reverse Stock Split, the Share Issuance
Proposal and the Adjournment Proposal as of immediately prior to
the opening of the polls at such meeting (the “Initial
Redemption Time”) will automatically be redeemed in whole,
but not in part, by the Company at the Initial Redemption Time
without further action on the part of the Company or the holder of
shares of Series C Preferred Stock (the “Initial
Redemption”). Any outstanding shares of Series C Preferred
Stock that have not been redeemed pursuant to an Initial Redemption
will be redeemed in whole, but not in part, (i) if such redemption
is ordered by the Board in its sole discretion, automatically and
effective on such time and date specified by the Board in its sole
discretion or (ii) automatically upon the approval by the
Corporation’s stockholders of the Reverse Stock Split and the Share
Increase Proposal at any meeting of stockholders held for the
purpose of voting on such proposals.
Each
share of Series C Preferred Stock redeemed in any redemption
described above will be redeemed in consideration for the right to
receive an amount equal to $0.10 in cash for each ten whole shares
of Series C Preferred Stock that are “beneficially owned” by the
“beneficial owner” (as such terms are defined in the certificate of
designation with respect to the Series C Preferred Stock (the
“Certificate of Designation”)) thereof as of
immediately prior to the applicable redemption time and redeemed
pursuant to such redemption. However, the redemption consideration
in respect of the shares of Series C Preferred Stock (or fractions
thereof) redeemed in any redemption described above: (i) will
entitle the former beneficial owners of less than ten whole shares
of Series C Preferred Stock redeemed in any redemption to no cash
payment in respect thereof and (y) will, in the case of a former
beneficial owner of a number of shares of Series C Preferred Stock
(or fractions thereof) redeemed pursuant to any redemption that is
not equal to a whole number that is a multiple of ten, entitle such
beneficial owner to the same cash payment, if any, in respect of
such redemption as would have been payable in such redemption to
such beneficial owner if the number of shares (or fractions
thereof) beneficially owned by such beneficial owner and redeemed
pursuant to such redemption were rounded down to the nearest whole
number that is a multiple of ten (such, that for example, the
former beneficial owner of 25 shares of Series C Preferred Stock
redeemed pursuant to any redemption will be entitled to receive the
same cash payment in respect of such redemption as would have been
payable to the former beneficial owner of 20 shares of Series C
Preferred Stock redeemed pursuant to such redemption).
The
Series C Preferred Stock is not convertible into, or exchangeable
for, shares of any other class or series of stock or other
securities of the Company. The Series C Preferred Stock has no
stated maturity and is not subject to any sinking fund. The Series
C Preferred Stock is not subject to any restriction on the
redemption or repurchase of shares by the Company while there is
any arrearage in the payment of dividends or sinking fund
installments.
The
Certificate of Designation was filed with the Delaware Secretary of
State and became effective on May 4, 2022. The foregoing
description of the Series C Preferred Stock does not purport to be
complete and is qualified in its entirety by reference to the
Certificate of Designation, which is filed as Exhibit 3.1 to this
Current Report and is incorporated herein by reference.
Item
7.01. Regulation FD Disclosure.
On
May 3, 2022, the Company issued a press release announcing the
Series C Preferred Stock dividend. A copy of that press release is
furnished as Exhibit 99.1 to this Current Report and incorporated
herein by reference.
In
accordance with General Instruction B.2 of Form 8-K, the
information Exhibit 99.1, which is incorporated into this Item
7.01, is being furnished pursuant to Item 7.01 and shall not be
deemed “filed” for the purposes of Section 18 of the Exchange Act,
or otherwise subject to the liabilities of that section, nor shall
it be deemed incorporated by reference in any filing under the
Securities Exchange Act of 1934, as amended, or the Securities Act
of 1933, as amended, except as shall be expressly set forth by
reference in such a filing.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits.
* *
*
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
ENVERIC BIOSCIENCES, INC. |
|
|
Date:
May 4, 2022 |
By: |
/s/
Joseph Tucker |
|
|
Joseph
Tucker |
|
|
Chief
Executive Officer |
Ameri (NASDAQ:AMRH)
Historical Stock Chart
From Feb 2023 to Mar 2023
Ameri (NASDAQ:AMRH)
Historical Stock Chart
From Mar 2022 to Mar 2023